
Calderasib (MK-1084) is a селективный KRAS G12C ингибитор demonstrating antitumor efficacy. It can be utilized as monotherapy or in combination with pembrolizumab () for oncology research.
Calderasib (MK-1084) is a selective KRAS G12C inhibitor demonstrating antitumor efficacy. It can be utilized as monotherapy or in combination with pembrolizumab () for oncology research.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.